Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Concomitant use with potent CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin). Hepatic impairment.
|
|
Special Precautions
Patient with psychiatric disorder, CV disorder, coronary artery disease. Renal impairment. Elderly. Pregnancy and lactation. Avoid abrupt dose reduction and withdrawal. Patient Counselling This drug may cause drowsiness, dizziness, and hypotension, if affected, do not drive or operate machinery. Monitoring Parameters Monitor LFT at baseline and monthly for the first 4 months of therapy. Monitor blood pressure, renal function, and ECG periodically.
|
|
Adverse Reactions
Significant: Hepatotoxicity, hypersensitivity reactions, hypotension, sedation, hallucinations.
Gastrointestinal disorders: Xerostomia.
General disorders and administration site conditions: Weakness, fatigue, withdrawal hypertension.
Infections and infestations: Infection.
Investigations: Increased liver enzymes.
Nervous system disorders: Dizziness, drowsiness.
Cardiac disorders: Bradycardia, tachycardia.
|
|
Drug Interactions
Enhanced CNS effects with sedatives and other CNS depressants (e.g. benzodiazepines, opioids, TCA). Increased hypotensive effects, rebound hypertension and tachycardia with β-adrenoceptor blockers, digoxin. Increased plasma concentration with oral contraceptives.
|
|
CIMS Class
|
|
ATC Classification
M03BX02 - tizanidine ; Belongs to the class of other centrally-acting muscle relaxants.
|
